A Study to Evaluate the Impact of Clacoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Acne Vulgaris Clinical Trial

Official title:

A Clinical Study to Assess the Barrier Impact of Winlevi

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06415292
• Other study ID #: DCS-94-23
• Status: Completed
• Phase: Phase 4
• Start date: November 27, 2023
• Est. completion date: December 16, 2023

Study information

• Verified date: February 2024
• Source: Sun Pharmaceutical Industries Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acne medications are a common source of facial dryness resulting in skin barrier damage and poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently prescribed and effective acne medications, however, dryness is an unwanted side effect. A new acne medication, 1% clascoterone, has been placed in a novel vehicle for excellent drug delivery in combination with excellent barrier properties. The barrier properties of 1% clascoterone have never been demonstrated. This study is aimed at better understanding the positive barrier effects of 1% clascoterone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 16, 2023
• Est. primary completion date: December 16, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects who self identify as having sensitive acne prone skin.

2. Female or male subjects 18+ years of age.

3. Subjects with Fitzpatrick skin types I-VI.

4. Subject agrees not to introduce any new colored cosmetics (lipsticks, eye shadows, facial foundations, blush, powder) or skin care products during the study.

5. Subjects must be willing to use only a cleanser and sunscreen on the entire face and no other skin care products.

6. Subjects must be willing to use the Winlevi study product to designated half face. No other topical acne treatment products on the entire face for the 2 week duration of the study.

7. Subject has signed an Informed Consent Form in compliance with 21CFR Part 50:

"Protection of Human Subjects."

8. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.

9. Subject is in generally good physical and mental health.

Exclusion Criteria:

1. Any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, except for the conditions associated with sensitive skin.

2. Subjects who are not willing to use only the assigned study product and nothing else one randomized half face, except for cleanser and sunscreen that must remain unchanged during the study. Moisturizers or topical acne treatment products should not be used during the 2 week study period on either side of the face.

3. Subjects who do not agree to refrain from direct sun exposure during the study duration.

4. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.

5. Subjects, who are pregnant, breast feeding, or planning a pregnancy.

6. Subjects with clinically significant unstable medical disorders.

7. Subjects who are unwilling or unable to comply with the requirements of the protocol.

8. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.

9. Subjects who are currently participating in any other clinical study.

10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.

11. Subjects who currently or frequently use high doses of anti-inflammatory drugs for a defined medication condition. Aspirin use should not exceed 2 tablets (650 mg) per day.

12. Subjects currently receiving any anticancer, immunosuppressive treatments/ medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), or radiation as determined by the initial paperwork.

13. Subjects with a history of immunosuppression/immune deficiency disorders (including (HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara) and/or radiation as determined by study documentation.

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Drug:
• Winlevi (clascoterone) 1% cream
Split face. Blinded study treatment product to be applied to the randomized half face

Locations

Country	Name	City	State
United States	Dermatology Consulting Services, PLLC	High Point	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Sun Pharmaceutical Industries Limited

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is the change in corneometry reading between the two sides of the face treated with Winlevi versus no treatment.		Week 2
Secondary	The secondary endpoint is the change in TEWL reading between the two sides of the face treated with Winlevi versus no treatment		Week 2